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Abstract:  27 
Cognitive decline is among the most feared aspects of ageing. We have generated induced pluripotent stem 28 
cells (iPSCs) from 24 people from the Lothian Birth Cohort 1936, whose cognitive ability was tested in 29 
childhood and in older age. Peripheral blood mononuclear cells (PBMCs) were reprogrammed using non-30 
integrating oriP/EBNA1 backbone plasmids expressing six iPSC reprogramming factors (OCT3/4 (POU5F1), 31 
SOX2, KLF4, L-Myc, shp53, Lin28, SV40LT). All lines demonstrated STR matched karyotype and pluripotency 32 
was validated by multiple methods. These iPSC lines are a valuable resource to study molecular mechanisms 33 
underlying individual differences in cognitive ageing and resilience to age-related neurodegenerative diseases. 34 
35 
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Resource Table:  1 


























Alternative names of stem cell lines N/A 
Institution Cedars-Sinai Medical Center, Los Angeles, USA 
 
 
Contact information of distributor USA distributer: Dhruv Sareen - dhruv.sareen@cshs.org 
 
UK distributor: Karen Burr – Karen.burr@ed.ac.uk 
 
Clinical data distributor: Paul Redmond – 
paul.redmond@ed.ac.uk 
Type of cell lines iPSC 
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Origin Human  
Cell Source  Peripheral Blood Mononuclear Cell 
Clonality Clonal 
Method of reprogramming Non-integrating episomal plasmids 
Multiline rationale  24 cell lines from a shared birth year/region cohort 
Gene modification NO 
Type of modification N/A 
Associated disease  N/A 
Gene/locus N/A 
Method of modification N/A 
Name of transgene or resistance N/A 
Inducible/constitutive system N/A 


























Cell line repository/bank The following lines have been added to the Cedars-Sinai iPSC 
Core Repository which can be viewed by the public online at 
https://biomanufacturing.cedars-sinai.org. Direct links to each 
























Ethical approval NHS Lothian Research Ethics Committee: 10/S1103/10. 
CSMC Induced Pluripotent Stem Cell (iPSC) Core Facility 
Repository and Stem Cell program IRB Protocol: Pro00032834 
 1 
Resource utility 2 
The neurobiology of cognitive ability and its decline during ageing are poorly understood. Human iPSC lines 3 
from the Lothian Birth Cohort 1936 comprise individuals with rich life-course cognitive performance data 4 
5 
 
(Taylor et al., 2018; Wardlaw et al., 2011), affording a rare model to investigate molecular mechanisms 1 
relevant to differences in brain development, cellular resilience, and vulnerability to pathology. 2 
 3 
Resource Details  4 
 5 
Human peripheral blood mononuclear cells (PBMCs) were obtained from 24 unrelated members of the 6 
Lothian Birth Cohort 1936. Demographic parameters are 50% female (n = 12), 100% white Scottish (Table 1). 7 
Line donors can be grouped into ‘successful’, ‘typical’, and ‘poor’ cognitive ageing categories (sFig.1). Exclusion 8 
criteria were: self-reported dementia, Parkinson’s disease or stroke, Mini Mental State Examination (MMSE 9 
score <24, as well as standardised childhood IQ scores (<65, Moray House Test No. 12 at age 11), and 10 
standardised adult IQ scores (<85, average of Moray House Test No. 12 at age 70 and 76).  11 
 12 
PBMCs were reprogrammed to generate induced pluripotent stem cells (iPSCs) using episomal plasmids 13 
encoding human OCT3/4 (POU5F1), SOX2, KLF4, L-Myc, shp53, Lin28, SV40LT. All lines were reprogrammed 14 
and stored within 22 months of each other. EBNA-related gene analysis demonstrated that iPSCs were EBNA 15 
transgene-free (and therefore exogenous reprogramming factors were no longer present) by passage 17-21 16 
(depending on line). Qualitative tests for parental cell type by TCR-αβ and TCR-γδ T-cell clonality assay 17 
revealed that 83% (n = 20) of lines were non-T cell-derived, 17% (n = 4) were T-cell derived. T-cell derived lines 18 
are: EDi021-A, EDi025-A, EDi026-A, and EDi035-A. All lines have been confirmed mycoplasma negative 19 
(sFig.27). 20 
 21 
All lines demonstrated stem cell-like morphology (Fig1F, sFig2-24F) and expressed six pluripotency markers 22 
(OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4) evaluated by immunocytochemistry (Fig.1B, sFig.2-24B). 23 
Additionally, all lines demonstrated positive alkaline phosphatase AP staining (Fig.1A, sFig.2-24A) and self-24 
renewal in undifferentiated iPSCs as assessed by PluriTest (Fig.1C, sFig.2-24C) and TaqMan®hPSC ScorecardTM 25 
Panel (Fig.1D, sFig.2-24E). However, whilst EDi035-A had a positive PluriTest and ScorecardTM pluripotency 26 
result, the PluriTest novelty score was borderline (1.688) (sFig.14C,E). Furthermore, EDi027-A also had a 27 
borderline positive ectoderm score as assessed by ScorecardTM (sFig.6E). At 14 days of embryoid body 28 
differentiation, all lines demonstrated tri-lineage potential except EDi022-A (negative endoderm, borderline 29 
mesoderm score, sFig.2E), EDi035-A (negative mesoderm, borderline endoderm score, sFig.14E), and EDi042-A 30 
(negative endoderm score, sFig.21E), as assessed by ScorecardTM. 31 
 32 
All lines showed a normal karyotype (Fig.1D, sFig. 2-24D) between passages 6-22, with one exception. All five 33 
clones of EDi-038-A (a male) karyotyped as monosomy (45,X) (sFig.18D), and thus very likely stems from the 34 
source PBMCs. Mosaicism is a relatively common and probably harmless finding in blood cultures from normal 35 
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females and, though rarer, also in males (Bukvic et al., 2001). No differences were detected between the 1 
original PBMC samples and the corresponding iPSC lines. 2 
 3 
All lines were confirmed to be of human origin and iPSCs matched the profile of parent PBMCs by Short 4 
Tandem Repeat (STR) analysis. Parent line data was not available for EDi026-A and EDi028-A. Genetic profiles 5 
for these lines were compared to the cell line genetic profiles available in the DSMZ STR database and did not 6 
match any other reported profiles in the DSMZ database. These profiles were found to be unique and did not 7 
match to any previously submitted profiles from the iPSC Core. The genetic profiles established here can be 8 
used for future comparisons for these cell lines. Whole genome sequence data for all 24 lines has been 9 
deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under 10 
accession number EGAS00001003819. 11 
 12 
An overview of iPSC line characterisation can be found in Table 2. Figure 1 presents example characterisation 13 
data from EDi021-A. Data for all other lines can be found in Supplementary Figures 2-27. 14 
 15 
Materials and Methods 16 
 17 
PBMC isolation 18 
Blood samples were collected with NHS Lothian Research Ethics Committee Approval (10/S1103/10). Blood 19 
samples were collected in Sodium Citrate BD Vacutainer CPT tubes (BD, Cat. 362761) (three tubes per 20 
participant). For samples EDi021-A, EDi025-A, EDi028-A, EDi030-A, EDi031-A, EDi032-A, EDi033-A, EDi034-A, 21 
and EDi035-A PBMC isolation was performed by Roslin Cells. For all other lines, PBMC isolation was performed 22 
by the Edinburgh Clinical Research Facility (ECRF).  23 
 24 
Generation of human iPSCs  25 
Generation of human iPSCs lines from PBMCs was performed using nucleofection of episomal plasmids 26 
containing POU5F1, SOX2, KLF4, LIN28, L-MYC, TP53shRNA, and SV40LT.  27 
 28 
Briefly, ~5×106 cells per nucleofection of PBMCs were nucleofected with the Amaxa Human T-cell 29 
Nucleofector® Kit (Lonza, Cat. VVPA-1002) and a 5p plasmid mixture using program V-024 on a Amaxa 30 
Nucleofector 2D Device (Lonza, Cat. AAB-1001). Each transfection contained the following seven factors: 31 
OCT4, SOX2, KLF4, LMYC, LIN28, SV40LT and p53 shRNA. These were delivered on the following plasmids from 32 
Addgene, together with an EBNA1 plasmid for episomal plasmid maintenance: pEP4 E02S ET2K (Cat. 20927), 33 
pCXLE-hOCT3/4-shp53-F (Cat. 27077), pCXLEhUL (Cat. 27080), pCXLE-hSK (Cat. 27078), and pCXWB-EBNA1 34 
(Cat. 37624). Each transfection used 0.5µg of plasmid pCXWB-EBNA1 and 0.83µg of each of the remaining four 35 
plasmids. After nucleofection, cells were immediately plated in either αβ T-cell medium (X-vivo10 [Lonza, Cat. 36 
7 
 
04-380Q] supplemented with 30U/ml IL-2 [ThermoFisher Scientific, Cat. PHC0026] and 5µl/well Dynabeads 1 
Human T-activator CD3/CD28 [Life Technologies, Cat. 11161D]) or non T-cell medium (αMEM [Life 2 
Technologies, Cat. 12561056] supplemented with 10% Heat Inactivated-FBS [Life Technologies, Cat. 3 
10437028], 10ng/ml IL-3 [StemCell Technologies, Cat. 78040.1], 10ng/ml IL-6 [StemCell Technologies, Cat. 4 
78050.1], 10ng/ml G-CSF [StemCell Technologies, Cat. 78012.1] and 10ng/ml GM-CSF [StemCell Technologies, 5 
Cat. 78015.1]) onto mitomycin treated mouse embryonic fibroblasts (MEF) and placed in a 37°C incubator 6 
with 20% O2 and 5% CO2. 7 
 8 
Two days after nucleofection, 2mL/well of Primate ESC medium (ReproCell, Cat. RCHEMD001) containing 9 
5ng/ml bFGF (for MEF condition) was added to the wells without aspirating the previous medium. Beginning 10 
on day four, the medium was gently aspirated from each well and 2mL of the appropriate fresh 11 
reprogramming media was added to each well. Medium was replaced every other day. At approximately day 12 
18 post nucleofection, individual colonies were observed in all wells of each condition. Individual PBMC-iPSC 13 
colonies with ES/iPSC-like morphology appeared between day 25-32 and those with best morphology were 14 
mechanically isolated, transferred onto 12-well plates with fresh Matrigel™ Matrix (Corning/BD Biosciences, 15 
Cat. 354230), and maintained in mTeSR®1 medium (StemCell Technologies, Cat. 85850). The iPSC clones were 16 
further expanded and scaled up for further analysis. All cultures were maintained at 37°C, 20% O2, and 5% CO2 17 
throughout the reprogramming process. 18 
 19 
iPSC maintenance and storage 20 
Human iPSCs were cultured in mTeSR®1 medium (StemCell Technologies, Cat. 85850) on growth factor-21 
reduced Matrigel™ Matrix (Corning, Cat. 354230) -coated plates at 37°C in a 20% O2, 5% CO2 incubator. Briefly, 22 
70–90% confluent human iPSC colonies were passaged every 7 days chemically (Versene, Life Technologies, 23 
Cat. 15040-066 or ReLeSR, StemCell Technologies, Cat. 05872) or mechanically by StemPro® EZPassage™ 24 
Disposable Stem Cell Passaging Tool (Life Technologies, Cat. 23181-010) and re-plated at a 1:6 or 1:9 ratio 25 
depending on the cell line. The iPSCs were passaged every 5-7 days. The iPSCs were expanded for 6-22 26 
passages during which period various characterization assays were performed. The iPSCs were cryopreserved 27 
using CryoStor CS10 (StemCell Technologies, Cat. 07930) and an isopropanol freezing vessel at -80°C 28 
overnight. The cryopreserved vials were subsequently stored in liquid nitrogen tanks for long-term storage. 29 
Working Cell Banks (WCB) of iPSCs were cryopreserved at passage 9-14 and then Distribution Cells Banks 30 
(DCB) were created between passages 18-22.  31 
 32 
Mycoplasma testing 33 
The absence of mycoplasma contamination in the iPSC lines were confirmed monthly using the MycoAlert 34 




EBNA-related gene analysis 1 
250ng of genomic DNA was extracted using the KingFisherTM DUO Prime purification system (Thermo Fisher 2 
Scientific) and the MagMAXTM DNA Multi-Sample Ultra 2.0 Kit (Applied Biosystems, A36570). An embryonic 3 
stem cell line (H9) was included alongside LBC lines a negative control. DNA Amplification was conducted 4 
using TaKaRa Ex Taq® DNA Polymerase (TaKaRa Bio, RR001) and a Bio Rad 1000 Touch Thermal Cycler.  5 
Primers that recognize EBNA1 along with housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase 6 
(GAPDH), which was used as a housekeeping gene, were included in this study (Table 2). PCR was run for 35 7 
cycles at 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds.  8 
 9 
TCRB and TCRG T-Cell Clonality Assay 10 
TCRB and TCRG T-Cell Clonality testing was conducted using Gene Rearrangement and Translocation assays 11 
from Invivoscribe Technologies, Inc. Genomic DNA was harvested from all iPSC lines using the MagMAXTM DNA 12 
Multi-Sample Ultra 2.0 Kit (Cat. A36570) from Applied Biosystems and it was re-suspended to a final 13 
concentration of 100-400μg per ml in dilution buffer. Three Clonal Control DNA and one Polyclonal Control 14 
DNA provided with the kit were used. PCR was carried out as per the manufacturer’s protocol. PCR products 15 
were analysed using 6% TBE gel electrophoresis with gel red staining.  16 
 17 
Karyotyping 18 
Human PBMC-iPSCs were incubated in Colcemid (100ng/mL; Life Technologies) for 30 minutes at 37°C and 19 
then dissociated using TrypLE for 5 minutes. They were then washed in phosphate buffered saline (PBS) and 20 
incubated at 37°C in 5mL hypotonic solution (1g KCl, 1g Na Citrate in 400mL water) for 30 minutes. The cells 21 
were centrifuged for 2.5 minutes at 1500RPM and re-suspended in fixative (methanol: acetic acid, 3:1) at 22 
room temperature for 5 minutes. This was repeated twice, and finally cells were re-suspended in 500μl of 23 
fixative solution and submitted to the Cedars-Sinai Clinical Cytogenetics Core for G-band karyotyping. 24 
Karyotyping of each iPSC line was conducted at early and late passage, between passages 6-22. Approximately 25 
20 metaphase spreads were counted per line. 26 
 27 
Immunocytochemistry 28 
iPSCs were plated on Matrigel™ (Corning, Cat. 354230) -coated glass coverslips or optical-bottom 96-well 29 
plates (ThermoFisher Scientific, Cat. 165305) and subsequently fixed in 4% paraformaldehyde (10 minutes, 30 
room temperature (RT)). The blocking buffer used was 5% goat serum (Millipore, Cat. S26-100ML) and 5% 31 
donkey serum (Millipore, S30-100ML) with 0.15% Triton X-100 in PBS, except for SSEA4 and OCT4 staining, for 32 
which 5% goat serum with 0.15% Triton X-100 in PBS was used as the block. All cells were blocked for one 33 
hour at RT, then incubated with primary antibodies (Table 3) for either 3 hours at RT or overnight at 4°C. Cells 34 
were then rinsed and incubated in species-specific AF488 or AF594-conjugated secondary antibodies (1:500, 35 
diluted in the same block as the primary antibodies) for one hour at RT, followed by DAPI (0.5-1μg/ml; Sigma) 36 
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to counterstain nuclei (10 minutes, RT). Cells were imaged using Nikon/Leica microscopes or Image Express. 1 
The iPSCs exhibited an embryonic stem cell like morphology, and expressed a range of pluripotency markers 2 
(OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4) (Figure 1B, Supplementary Figures 2-24B). 3 
 4 
Alkaline phosphatase staining 5 
Alkaline phosphatase staining was performed using the Alkaline Phosphatase Staining Kit II (Stemgent, Cat. 00-6 
0055) according to the manufacturer's instructions.  7 
 8 
PluriTest 9 
PluriTest was used to assess the pluripotency of undifferentiated iPSCs (Figure 1C, Supplementary Figures 2-10 
24C). Cell pellets were sent to Life Technologies Corporation for the PluriTest Service. Total RNA was isolated 11 
using the PureLinkTM RNA Mini Kit (Thermo Fisher Scientific) and quantified using NanoDropTM. 100ng total 12 
RNA was used to prepare the GeneChip® for the PluriTest™. In this assay, 36,000 transcripts and variants 13 
against a >450 sample reference set are assessed for gene expression analysis. A non-iPSC sample was used in 14 
this experiment to serve as a control for non-pluripotency. The transcriptome of all samples were analysed 15 
and processed in the PluriTest™ algorithm to generate a pluripotency and novelty score. These two scores 16 
determine the pluripotency signature of the cell line which is represented in the pluripotency plot. The 17 
threshold for pluripotency was >20, and the threshold for novelty was <1.6. 18 
 19 
hPSC Scorecard Data Analysis  20 
Applied Biosystems TaqMan®hPSC ScorecardTM Panel (Thermo Fisher Scientific) was used as an additional 21 
technique to assess pluripotency and tri-lineage differentiation potential of iPSC lines using real-time qPCR 22 
assays (Figure 1E, Supplementary Figures 2-24E). Total RNA from undifferentiated and EB differentiated iPSC 23 
lines was isolated using MagMAXTM mirVanaTM Total RNA Isolation Kit (A27828), and 1μg of RNA was used to 24 
make cDNA using the High Capacity cDNA Reverse Transcription Kit (4368813), both from Applied Biosystems. 25 
TaqMan qRT-PCR was carried out using the hPSC Scorecard 384w Fast plate (Life technologies, A15870) and 26 
QuantStudio 12k Flex, following manufacturer protocol. We analysed the gene expression data from the 27 
TaqMan®hPSC ScorecardTM Panel using the web-based hPSC ScorecardTM Analysis Software (Thermo Fisher 28 
Scientific).  29 
 30 
Embryoid Body (EB) Formation 31 
IPSC lines were allowed to differentiate by EB formation. Briefly, iPSCs were lifted from 3 wells of a 6 well 32 
plate using a cell scraper and seeded in a T25 flask treated with poly-HEMA to prevent cell attachment in EB 33 
media containing: IMDM basal media (Cat. 12440061), 17% KnockOut Serum Replacement (KOSR; Cat. 34 
10828028), 1% non-essential amino acids (Cat. 11140050), 1% Antibiotic-Antimycotic (Cat. 15240062) and 35 
110µM β-Mercaptoethanol (Cat. 21985023), all from Thermo Fisher. EBs were allowed to form by self-36 
10 
 
aggregation, grow and differentiate for 14 days in EB culture media replacing it twice a week. Differentiation 1 
to endoderm, mesoderm and ectoderm was assessed by TaqMan® hPSC Scorecard™ Assay (Figure 1E, 2 
Supplementary Figures 2-24E). 3 
 4 
 5 
STR Analysis 6 
Short Tandem Repeat (STR) Analysis is conducted to confirm iPSC genetic identity. For that, a frozen vial of the 7 
parent PBMCs and a frozen vial of the reprogramed iPSC line at late passage (18-21, depending on the cell 8 
line) are sent to IDEXX BioResearch. STR profile and interspecies contamination testing is analysed. iPSC line 9 
human authentication was conducted at IDEXX BioResearch by Cell CheckTM. Profiling included using a nine 10 
marker STR profile (AMEL, CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX and vWA) and 11 
interspecies contamination check for human, mouse, rat, African green monkey and Chinese hamster cells. 12 
Comparative analysis was conducted between parent PBMCs and reprogrammed iPSC lines. 13 
 14 
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Gender Age at 
collection 
Ethnicity Genotype of 
locus 
Disease 
EDi021-A  M 78.8 White 
Scottish 
N/A N/A 
EDi022-A  M 79.22 White 
Scottish 
N/A N/A 


















































































































Table 2: Characterization and validation 1 
 2 
Classification Test Result Data 
Morphology  Photography of phase 
contrast. 
Normal. Colonies of small 























Pluripotency score ≥ 20 





Genotype Karyotype (G-banding). Normal XX and XY 
corresponding to gender 









9 loci tested. 100% match 
for lines where original 
PBMCs were available 
(22/24 lines). 
Available with the 
authors. 
N/A N/A 
Mutation analysis (IF 
APPLICABLE) 
  
Sequencing. N/A N/A 
Southern Blot OR WGS. N/A N/A 
Microbiology and 
virology 






ectoderm negative at day 













Blood group genotyping. N/A N/A 





Table 3: Reagents details 1 
Antibodies used for immunocytochemistry/flow-cytometry 
  Antibody Dilution Company Cat # and RRID  






OCT4 (Rabbit, IgG) 
 
NANOG (Rabbit, IgG) 
 












Stemgent (cat. 09-0006, RRID: 
AB_1512169) 
Stemgent (cat. 09-0010, RRID:  
AB_1512170) 
Stemgent (cat. 09-0011, RRID:  
AB_1512171) 
Stemgent (cat. 09-0023, RRID: 
AB_2167689) 
Stemgent (cat. 09-0020, RRID: 
AB_2298294) 
Stemgent (cat. 09-0024, RRID: 
AB_2195775) 
N/A N/A N/A N/A 
Secondary antibodies Donkey anti-Mouse IgG 
AF488 
Donkey anti-Rabbit IgG 
AF594 
Goat anti-Mouse IgG, 
IgM, IgA  AF488 
 
1:500 Life Technologies (cat. A-21202) 
Life Technologies (cat. A-21207) 
Life Technologies (cat. A-10667) 
Primers 
 Target Forward/Reverse primer (5′-3′) 
Episomal Plasmids (qPCR) Epstein-Barr virus 
nuclear antigen (EBNA) 
GGTCCCGAGAATCCCCATCC/ 
TTCATGGTCGCTGTCAGACAG 









N/A N/A N/A 
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h) Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 21 
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j) Oxford Parkinson’s Disease Centre, Oxford, UK. 23 
k) Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK. 24 
ǂ Corresponding authors. 25 
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Abstract:  27 
Cognitive decline is among the most feared aspects of ageing. We have generated induced pluripotent stem 28 
cells (iPSCs) from 24 people from the Lothian Birth Cohort 1936, whose cognitive ability was tested in 29 
childhood and in older age. Peripheral blood mononuclear cells (PBMCs) were reprogrammed using non-30 
integrating oriP/EBNA1 backbone plasmids expressing six iPSC reprogramming factors (OCT3/4 (POU5F1), 31 
SOX2, KLF4, L-Myc, shp53, Lin28, SV40LT). All lines demonstrated STR matched karyotype and pluripotency 32 
was validated by multiple methods. These iPSC lines are a valuable resource to study molecular mechanisms 33 





Resource Table:  1 


























Alternative names of stem cell lines N/A 
Institution Cedars-Sinai Medical Center, Los Angeles, USA 
 
 
Contact information of distributor USA distributer: Dhruv Sareen - dhruv.sareen@cshs.org 
 
UK distributor: Karen Burr – Karen.burr@ed.ac.uk 
 
Clinical data distributor: Paul Redmond – 
paul.redmond@ed.ac.uk 
Type of cell lines iPSC 
3 
 
Origin Human  
Cell Source  Peripheral Blood Mononuclear Cell 
Clonality Clonal 
Method of reprogramming Non-integrating episomal plasmids 
Multiline rationale  24 cell lines from a shared birth year/region cohort 
Gene modification NO 
Type of modification N/A 
Associated disease  N/A 
Gene/locus N/A 
Method of modification N/A 
Name of transgene or resistance N/A 
Inducible/constitutive system N/A 


























Cell line repository/bank The following lines have been added to the Cedars-Sinai iPSC 
Core Repository which can be viewed by the public online at 
https://biomanufacturing.cedars-sinai.org. Direct links to each 
























Ethical approval NHS Lothian Research Ethics Committee: 10/S1103/10. 
CSMC Induced Pluripotent Stem Cell (iPSC) Core Facility 
Repository and Stem Cell program IRB Protocol: Pro00032834 
 1 
Resource utility 2 
The neurobiology of cognitive ability and its decline during ageing are poorly understood. Human iPSC lines 3 
from the Lothian Birth Cohort 1936 comprise individuals with rich life-course cognitive performance data 4 
5 
 
(Taylor et al., 2018; Wardlaw et al., 2011), affording a rare model to investigate molecular mechanisms 1 
relevant to differences in brain development, cellular resilience, and vulnerability to pathology. 2 
 3 
Resource Details  4 
 5 
Human peripheral blood mononuclear cells (PBMCs) were obtained from 24 unrelated members of the 6 
Lothian Birth Cohort 1936. Demographic parameters are 50% female (n = 12), 100% white Scottish (Table 1). 7 
Line donors can be grouped into ‘successful’, ‘typical’, and ‘poor’ cognitive ageing categories (sFig.1). Exclusion 8 
criteria were: self-reported dementia, Parkinson’s disease or stroke, Mini Mental State Examination (MMSE 9 
score <24, as well as standardised childhood IQ scores (<65, Moray House Test No. 12 at age 11), and 10 
standardised adult IQ scores (<85, average of Moray House Test No. 12 at age 70 and 76).  11 
 12 
PBMCs were reprogrammed to generate induced pluripotent stem cells (iPSCs) using episomal plasmids 13 
encoding human OCT3/4 (POU5F1), SOX2, KLF4, L-Myc, shp53, Lin28, SV40LT. All lines were reprogrammed 14 
and stored within 22 months of each other. EBNA-related gene analysis demonstrated that iPSCs were EBNA 15 
transgene-free (and therefore exogenous reprogramming factors were no longer present) by passage 17-21 16 
(depending on line). Qualitative tests for parental cell type by TCR-αβ and TCR-γδ T-cell clonality assay 17 
revealed that 83% (n = 20) of lines were non-T cell-derived, 17% (n = 4) were T-cell derived. T-cell derived lines 18 
are: EDi021-A, EDi025-A, EDi026-A, and EDi035-A. All lines have been confirmed mycoplasma negative 19 
(sFig.27). 20 
 21 
All lines demonstrated stem cell-like morphology (Fig1F, sFig2-24F) and expressed six pluripotency markers 22 
(OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4) evaluated by immunocytochemistry (Fig.1B, sFig.2-24B). 23 
Additionally, all lines demonstrated positive alkaline phosphatase AP staining (Fig.1A, sFig.2-24A) and self-24 
renewal in undifferentiated iPSCs as assessed by PluriTest (Fig.1C, sFig.2-24C) and TaqMan®hPSC ScorecardTM 25 
Panel (Fig.1D, sFig.2-24E). However, whilst EDi035-A had a positive PluriTest and ScorecardTM pluripotency 26 
result, the PluriTest novelty score was borderline (1.688) (sFig.14C,E). Furthermore, EDi027-A also had a 27 
borderline positive ectoderm score as assessed by ScorecardTM (sFig.6E). At 14 days of embryoid body 28 
differentiation, all lines demonstrated tri-lineage potential except EDi022-A (negative endoderm, borderline 29 
mesoderm score, sFig.2E), EDi035-A (negative mesoderm, borderline endoderm score, sFig.14E), and EDi042-A 30 
(negative endoderm score, sFig.21E), as assessed by ScorecardTM. 31 
 32 
All lines showed a normal karyotype (Fig.1D, sFig. 2-24D) between passages 6-22, with one exception. All five 33 
clones of EDi-038-A (a male) karyotyped as monosomy (45,X) (sFig.18D), and thus very likely stems from the 34 
source PBMCs. Mosaicism is a relatively common and probably harmless finding in blood cultures from normal 35 
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females and, though rarer, also in males (Bukvic et al., 2001). No differences were detected between the 1 
original PBMC samples and the corresponding iPSC lines. 2 
 3 
All lines were confirmed to be of human origin and iPSCs matched the profile of parent PBMCs by Short 4 
Tandem Repeat (STR) analysis. Parent line data was not available for EDi026-A and EDi028-A. Genetic profiles 5 
for these lines were compared to the cell line genetic profiles available in the DSMZ STR database and did not 6 
match any other reported profiles in the DSMZ database. These profiles were found to be unique and did not 7 
match to any previously submitted profiles from the iPSC Core. The genetic profiles established here can be 8 
used for future comparisons for these cell lines. Whole genome sequence data for all 24 lines has been 9 
deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under 10 
accession number EGAS00001003819. 11 
 12 
An overview of iPSC line characterisation can be found in Table 2. Figure 1 presents example characterisation 13 
data from EDi021-A. Data for all other lines can be found in Supplementary Figures 2-27. 14 
 15 
Materials and Methods 16 
 17 
PBMC isolation 18 
Blood samples were collected with NHS Lothian Research Ethics Committee Approval (10/S1103/10). Blood 19 
samples were collected in Sodium Citrate BD Vacutainer CPT tubes (BD, Cat. 362761) (three tubes per 20 
participant). For samples EDi021-A, EDi025-A, EDi028-A, EDi030-A, EDi031-A, EDi032-A, EDi033-A, EDi034-A, 21 
and EDi035-A PBMC isolation was performed by Roslin Cells. For all other lines, PBMC isolation was performed 22 
by the Edinburgh Clinical Research Facility (ECRF).  23 
 24 
Generation of human iPSCs  25 
Generation of human iPSCs lines from PBMCs was performed using nucleofection of episomal plasmids 26 
containing POU5F1, SOX2, KLF4, LIN28, L-MYC, TP53shRNA, and SV40LT.  27 
 28 
Briefly, ~5×106 cells per nucleofection of PBMCs were nucleofected with the Amaxa Human T-cell 29 
Nucleofector® Kit (Lonza, Cat. VVPA-1002) and a 5p plasmid mixture using program V-024 on a Amaxa 30 
Nucleofector 2D Device (Lonza, Cat. AAB-1001). Each transfection contained the following seven factors: 31 
OCT4, SOX2, KLF4, LMYC, LIN28, SV40LT and p53 shRNA. These were delivered on the following plasmids from 32 
Addgene, together with an EBNA1 plasmid for episomal plasmid maintenance: pEP4 E02S ET2K (Cat. 20927), 33 
pCXLE-hOCT3/4-shp53-F (Cat. 27077), pCXLEhUL (Cat. 27080), pCXLE-hSK (Cat. 27078), and pCXWB-EBNA1 34 
(Cat. 37624). Each transfection used 0.5µg of plasmid pCXWB-EBNA1 and 0.83µg of each of the remaining four 35 
plasmids. After nucleofection, cells were immediately plated in either αβ T-cell medium (X-vivo10 [Lonza, Cat. 36 
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04-380Q] supplemented with 30U/ml IL-2 [ThermoFisher Scientific, Cat. PHC0026] and 5µl/well Dynabeads 1 
Human T-activator CD3/CD28 [Life Technologies, Cat. 11161D]) or non T-cell medium (αMEM [Life 2 
Technologies, Cat. 12561056] supplemented with 10% Heat Inactivated-FBS [Life Technologies, Cat. 3 
10437028], 10ng/ml IL-3 [StemCell Technologies, Cat. 78040.1], 10ng/ml IL-6 [StemCell Technologies, Cat. 4 
78050.1], 10ng/ml G-CSF [StemCell Technologies, Cat. 78012.1] and 10ng/ml GM-CSF [StemCell Technologies, 5 
Cat. 78015.1]) onto mitomycin treated mouse embryonic fibroblasts (MEF) and placed in a 37°C incubator 6 
with 20% O2 and 5% CO2. 7 
 8 
Two days after nucleofection, 2mL/well of Primate ESC medium (ReproCell, Cat. RCHEMD001) containing 9 
5ng/ml bFGF (for MEF condition) was added to the wells without aspirating the previous medium. Beginning 10 
on day four, the medium was gently aspirated from each well and 2mL of the appropriate fresh 11 
reprogramming media was added to each well. Medium was replaced every other day. At approximately day 12 
18 post nucleofection, individual colonies were observed in all wells of each condition. Individual PBMC-iPSC 13 
colonies with ES/iPSC-like morphology appeared between day 25-32 and those with best morphology were 14 
mechanically isolated, transferred onto 12-well plates with fresh Matrigel™ Matrix (Corning/BD Biosciences, 15 
Cat. 354230), and maintained in mTeSR®1 medium (StemCell Technologies, Cat. 85850). The iPSC clones were 16 
further expanded and scaled up for further analysis. All cultures were maintained at 37°C, 20% O2, and 5% CO2 17 
throughout the reprogramming process. 18 
 19 
iPSC maintenance and storage 20 
Human iPSCs were cultured in mTeSR®1 medium (StemCell Technologies, Cat. 85850) on growth factor-21 
reduced Matrigel™ Matrix (Corning, Cat. 354230) -coated plates at 37°C in a 20% O2, 5% CO2 incubator. Briefly, 22 
70–90% confluent human iPSC colonies were passaged every 7 days chemically (Versene, Life Technologies, 23 
Cat. 15040-066 or ReLeSR, StemCell Technologies, Cat. 05872) or mechanically by StemPro® EZPassage™ 24 
Disposable Stem Cell Passaging Tool (Life Technologies, Cat. 23181-010) and re-plated at a 1:6 or 1:9 ratio 25 
depending on the cell line. The iPSCs were passaged every 5-7 days. The iPSCs were expanded for 6-22 26 
passages during which period various characterization assays were performed. The iPSCs were cryopreserved 27 
using CryoStor CS10 (StemCell Technologies, Cat. 07930) and an isopropanol freezing vessel at -80°C 28 
overnight. The cryopreserved vials were subsequently stored in liquid nitrogen tanks for long-term storage. 29 
Working Cell Banks (WCB) of iPSCs were cryopreserved at passage 9-14 and then Distribution Cells Banks 30 
(DCB) were created between passages 18-22.  31 
 32 
Mycoplasma testing 33 
The absence of mycoplasma contamination in the iPSC lines were confirmed monthly using the MycoAlert 34 




EBNA-related gene analysis 1 
250ng of genomic DNA was extracted using the KingFisherTM DUO Prime purification system (Thermo Fisher 2 
Scientific) and the MagMAXTM DNA Multi-Sample Ultra 2.0 Kit (Applied Biosystems, A36570). An embryonic 3 
stem cell line (H9) was included alongside LBC lines a negative control. DNA Amplification was conducted 4 
using TaKaRa Ex Taq® DNA Polymerase (TaKaRa Bio, RR001) and a Bio Rad 1000 Touch Thermal Cycler.  5 
Primers that recognize EBNA1 along with housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase 6 
(GAPDH), which was used as a housekeeping gene, were included in this study (Table 2). PCR was run for 35 7 
cycles at 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds.  8 
 9 
TCRB and TCRG T-Cell Clonality Assay 10 
TCRB and TCRG T-Cell Clonality testing was conducted using Gene Rearrangement and Translocation assays 11 
from Invivoscribe Technologies, Inc. Genomic DNA was harvested from all iPSC lines using the MagMAXTM DNA 12 
Multi-Sample Ultra 2.0 Kit (Cat. A36570) from Applied Biosystems and it was re-suspended to a final 13 
concentration of 100-400μg per ml in dilution buffer. Three Clonal Control DNA and one Polyclonal Control 14 
DNA provided with the kit were used. PCR was carried out as per the manufacturer’s protocol. PCR products 15 
were analysed using 6% TBE gel electrophoresis with gel red staining.  16 
 17 
Karyotyping 18 
Human PBMC-iPSCs were incubated in Colcemid (100ng/mL; Life Technologies) for 30 minutes at 37°C and 19 
then dissociated using TrypLE for 5 minutes. They were then washed in phosphate buffered saline (PBS) and 20 
incubated at 37°C in 5mL hypotonic solution (1g KCl, 1g Na Citrate in 400mL water) for 30 minutes. The cells 21 
were centrifuged for 2.5 minutes at 1500RPM and re-suspended in fixative (methanol: acetic acid, 3:1) at 22 
room temperature for 5 minutes. This was repeated twice, and finally cells were re-suspended in 500μl of 23 
fixative solution and submitted to the Cedars-Sinai Clinical Cytogenetics Core for G-band karyotyping. 24 
Karyotyping of each iPSC line was conducted at early and late passage, between passages 6-22. Approximately 25 
20 metaphase spreads were counted per line. 26 
 27 
Immunocytochemistry 28 
iPSCs were plated on Matrigel™ (Corning, Cat. 354230) -coated glass coverslips or optical-bottom 96-well 29 
plates (ThermoFisher Scientific, Cat. 165305) and subsequently fixed in 4% paraformaldehyde (10 minutes, 30 
room temperature (RT)). The blocking buffer used was 5% goat serum (Millipore, Cat. S26-100ML) and 5% 31 
donkey serum (Millipore, S30-100ML) with 0.15% Triton X-100 in PBS, except for SSEA4 and OCT4 staining, for 32 
which 5% goat serum with 0.15% Triton X-100 in PBS was used as the block. All cells were blocked for one 33 
hour at RT, then incubated with primary antibodies (Table 3) for either 3 hours at RT or overnight at 4°C. Cells 34 
were then rinsed and incubated in species-specific AF488 or AF594-conjugated secondary antibodies (1:500, 35 
diluted in the same block as the primary antibodies) for one hour at RT, followed by DAPI (0.5-1μg/ml; Sigma) 36 
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to counterstain nuclei (10 minutes, RT). Cells were imaged using Nikon/Leica microscopes or Image Express. 1 
The iPSCs exhibited an embryonic stem cell like morphology, and expressed a range of pluripotency markers 2 
(OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4) (Figure 1B, Supplementary Figures 2-24B). 3 
 4 
Alkaline phosphatase staining 5 
Alkaline phosphatase staining was performed using the Alkaline Phosphatase Staining Kit II (Stemgent, Cat. 00-6 
0055) according to the manufacturer's instructions.  7 
 8 
PluriTest 9 
PluriTest was used to assess the pluripotency of undifferentiated iPSCs (Figure 1C, Supplementary Figures 2-10 
24C). Cell pellets were sent to Life Technologies Corporation for the PluriTest Service. Total RNA was isolated 11 
using the PureLinkTM RNA Mini Kit (Thermo Fisher Scientific) and quantified using NanoDropTM. 100ng total 12 
RNA was used to prepare the GeneChip® for the PluriTest™. In this assay, 36,000 transcripts and variants 13 
against a >450 sample reference set are assessed for gene expression analysis. A non-iPSC sample was used in 14 
this experiment to serve as a control for non-pluripotency. The transcriptome of all samples were analysed 15 
and processed in the PluriTest™ algorithm to generate a pluripotency and novelty score. These two scores 16 
determine the pluripotency signature of the cell line which is represented in the pluripotency plot. The 17 
threshold for pluripotency was >20, and the threshold for novelty was <1.6. 18 
 19 
hPSC Scorecard Data Analysis  20 
Applied Biosystems TaqMan®hPSC ScorecardTM Panel (Thermo Fisher Scientific) was used as an additional 21 
technique to assess pluripotency and tri-lineage differentiation potential of iPSC lines using real-time qPCR 22 
assays (Figure 1E, Supplementary Figures 2-24E). Total RNA from undifferentiated and EB differentiated iPSC 23 
lines was isolated using MagMAXTM mirVanaTM Total RNA Isolation Kit (A27828), and 1μg of RNA was used to 24 
make cDNA using the High Capacity cDNA Reverse Transcription Kit (4368813), both from Applied Biosystems. 25 
TaqMan qRT-PCR was carried out using the hPSC Scorecard 384w Fast plate (Life technologies, A15870) and 26 
QuantStudio 12k Flex, following manufacturer protocol. We analysed the gene expression data from the 27 
TaqMan®hPSC ScorecardTM Panel using the web-based hPSC ScorecardTM Analysis Software (Thermo Fisher 28 
Scientific).  29 
 30 
Embryoid Body (EB) Formation 31 
IPSC lines were allowed to differentiate by EB formation. Briefly, iPSCs were lifted from 3 wells of a 6 well 32 
plate using a cell scraper and seeded in a T25 flask treated with poly-HEMA to prevent cell attachment in EB 33 
media containing: IMDM basal media (Cat. 12440061), 17% KnockOut Serum Replacement (KOSR; Cat. 34 
10828028), 1% non-essential amino acids (Cat. 11140050), 1% Antibiotic-Antimycotic (Cat. 15240062) and 35 
110µM β-Mercaptoethanol (Cat. 21985023), all from Thermo Fisher. EBs were allowed to form by self-36 
10 
 
aggregation, grow and differentiate for 14 days in EB culture media replacing it twice a week. Differentiation 1 
to endoderm, mesoderm and ectoderm was assessed by TaqMan® hPSC Scorecard™ Assay (Figure 1E, 2 
Supplementary Figures 2-24E). 3 
 4 
 5 
STR Analysis 6 
Short Tandem Repeat (STR) Analysis is conducted to confirm iPSC genetic identity. For that, a frozen vial of the 7 
parent PBMCs and a frozen vial of the reprogramed iPSC line at late passage (18-21, depending on the cell 8 
line) are sent to IDEXX BioResearch. STR profile and interspecies contamination testing is analysed. iPSC line 9 
human authentication was conducted at IDEXX BioResearch by Cell CheckTM. Profiling included using a nine 10 
marker STR profile (AMEL, CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX and vWA) and 11 
interspecies contamination check for human, mouse, rat, African green monkey and Chinese hamster cells. 12 
Comparative analysis was conducted between parent PBMCs and reprogrammed iPSC lines. 13 
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Gender Age at 
collection 
Ethnicity Genotype of 
locus 
Disease 
EDi021-A  M 78.8 White 
Scottish 
N/A N/A 
EDi022-A  M 79.22 White 
Scottish 
N/A N/A 


















































































































Table 2: Characterization and validation 1 
 2 
Classification Test Result Data 
Morphology  Photography of phase 
contrast. 
Normal. Colonies of small 























Pluripotency score ≥ 20 





Genotype Karyotype (G-banding). Normal XX and XY 
corresponding to gender 









9 loci tested. 100% match 
for lines where original 
PBMCs were available 
(22/24 lines). 
Available with the 
authors. 
N/A N/A 
Mutation analysis (IF 
APPLICABLE) 
  
Sequencing. N/A N/A 
Southern Blot OR WGS. N/A N/A 
Microbiology and 
virology 






ectoderm negative at day 













Blood group genotyping. N/A N/A 





Table 3: Reagents details 1 
Antibodies used for immunocytochemistry/flow-cytometry 
  Antibody Dilution Company Cat # and RRID  






OCT4 (Rabbit, IgG) 
 
NANOG (Rabbit, IgG) 
 












Stemgent (cat. 09-0006, RRID: 
AB_1512169) 
Stemgent (cat. 09-0010, RRID:  
AB_1512170) 
Stemgent (cat. 09-0011, RRID:  
AB_1512171) 
Stemgent (cat. 09-0023, RRID: 
AB_2167689) 
Stemgent (cat. 09-0020, RRID: 
AB_2298294) 
Stemgent (cat. 09-0024, RRID: 
AB_2195775) 
N/A N/A N/A N/A 
Secondary antibodies Donkey anti-Mouse IgG 
AF488 
Donkey anti-Rabbit IgG 
AF594 
Goat anti-Mouse IgG, 
IgM, IgA  AF488 
 
1:500 Life Technologies (cat. A-21202) 
Life Technologies (cat. A-21207) 
Life Technologies (cat. A-10667) 
Primers 
 Target Forward/Reverse primer (5′-3′) 
Episomal Plasmids (qPCR) Epstein-Barr virus 
nuclear antigen (EBNA) 
GGTCCCGAGAATCCCCATCC/ 
TTCATGGTCGCTGTCAGACAG 









N/A N/A N/A 





Figure 1: Characterization for iPSC line EDi021-A  2 
 3 
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Selection of iPSC line donors based on cognitive ageing
sFig1: Selection of iPSC candidates based on 
cognitive ageing profiles in the Lothian Birth 
Cohort 1936. Dashed lines are added to show 
±1SD from the mean for the age 11 Moray House 
Test (MHT) score and ±1 and 2SDs from the mean 
for later-life MHT score.
Supplementary Material
D. G-Band karyotypeC. PluriTest
A. AP
TRA 1-81  SOX2 DAPI
B. Immunocytochemistry
E. hPSC Scorecard 
sFig.2: Characterization for iPSC line EDi022-A 
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sFig.3: Characterization for iPSC line EDi023-A 
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sFig.4: Characterization for iPSC line EDi025-A
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sFig.6: Characterization for iPSC line EDi027-A
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sFig.7: Characterization for iPSC line EDi028-A 
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sFig.8: Characterization for iPSC line EDi029-A 
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sFig.9: Characterization for iPSC line EDi030-A
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sFig.10: Characterization for iPSC line EDi031-A 
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sFig.11: Characterization for iPSC line EDi032-A 
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sFig.12: Characterization for iPSC line EDi033-A
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sFig.14: Characterization for iPSC line EDi035-A 
TRA 1-60  NANOG DAPISSEA4 OCT3/4 DAPI
100 µm 100 µm100 µm










D. G -Band karyotypeC. Pluritest
A. AP
TRA 1-81  SOX2 DAPI
B. Immunocytochemistry
E. hPSC Scorecard 
sFig.15: Characterization for iPSC line EDi036-A
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sFig.16: Characterization for iPSC line EDi037-A
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sFig.17: Characterization for iPSC line EDi038-A 
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sFig.18: Characterization for iPSC line EDi039-A 
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sFig.19: Characterization for iPSC line EDi040-A
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sFig.20: Characterization for iPSC line EDi041-A 
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sFig.21: Characterization for iPSC line EDi042-A
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sFig.22: Characterization for iPSC line EDi043-A 
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sFig.23: Characterization for iPSC line EDi044-A 
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sFig.24: Characterization for iPSC line EDi045-A
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sFig.25: EBNA assay for LBC lines
sFig25: 2% Agarose Gel images showing lack of EBNA persistence in all 
LBC iPSC lines. 77iSMA-n5 p21 = positive control iPSC for EBNA 
persistence. H9 p56 = Human ESC line H9, negative control for EBNA
sFig.26: T-cell Clonality
A) TCRB Tube A(240-285bp)
Target: Vẞ +Jẞ1/2
E) TCRG Tube B(80-220bp)
Target: Vg9 and Vg11+ Jg1.3/2.3
sFig26: Data showing T-cell clonal lineage for LBC iPSCs. For each line, three targets (Vẞ +Jẞ1/2, Vẞ 
+Jẞ2 and Dẞ +Jẞ1/2) were tested for T-Cell Receptor Beta Chain (TCRB), and two targets (Vg1-8, 
Vg10+Jg1.3/2.3; Vg9 and Vg11+ Jg1.3/2.3) for T-Cell Receptor Gamma Chain (TCRG). A-B-C) 
Representative 6% TBE Gel image for TCRB. D-E) Representative 6% TBE Gel image for TCRG. F) 
Representative 6% TBE Gel image for Control Genes. G) Table listing each of the LBC iPSC lines, 
indicating positivity (+) or negativity (-) for each of the T-cell receptors. Lines were considered positive if 
any band was present in any of the samples.
G)
F) Specimen Control Size Ladder
Target: Multiple Genes 
B) TCRB Tube B(240-285bp)
Target: Vẞ +Jẞ2 Line Passage TCRB TCRG
EDi021-A p17 + +
EDi022-A p4 - -
EDi023-A p3 - -
EDi025-A p25 - -
EDi026-A p20 - +
EDi027-A p5 - -
EDi028-A p3 - -
EDi029-A p4 - -
EDi030-A p6 - -
EDi031-A p23 - -
EDi032-A p4 - -
EDi033-A p17 - -
EDi034-A p21 - -
EDi035-A p4 + +
EDi036-A p6 - -
EDi037-A p6 - -
EDi038-A p12 - -
EDi039-A p7 + +
EDi040-A p4 - -
EDi041-A p4 - -
EDi042-A p6 - -
EDi043-A p3 - -
EDi044-A p4 - -
EDi045-A p19 - -
C) TCRB Tube C(170-210bp),
(285-325bp).Target: Dẞ +Jẞ1/2














sFig.27: Data showing the results 
of mycoplasma testing from iPSCs 
stored at two sites. A) PCR 
conducted by IDEXX BioAnalytics
for samples provided by Cedars-
Sinai Medical Center. All 24 LBC 
lines shown in green, positive 
control in red. B) Table showing 
results of MycoAlert Lonza LT07-
318 assay conducted by Dementias 
Platform UK for available lines. 
Ratio values stated are the ratio of 
the luminescence signal of the kit 
substrate to that of the kit reagent. 
A ratio of 0-0.999 is negative for 
mycoplasma, 1–1.3 is borderline 
(requiring retest), and >1.3 is 
positive for mycoplasma. All 



















EDi021-A p24 0.3 -
EDi022-A p13 0.52 -
EDi023-A p17 0.5 -
EDi025-A p23 0.5 -
EDi026-A p11 0.36 -
EDi027-A p13 0.45 -
EDi028-A p24 0.57
EDi029-A p14 0.38 -
EDi030-A p14 0.4 -
EDi031-A p29 0.45 -
EDi032-A p11 0.45 -
EDi033-A
EDi034-A p17 0.46 -
EDi035-A p17 0.47 -
EDi036-A p13 0.54 -
EDi037-A p20 0.39 -
EDi038-A
EDi039-A
EDi040-A p17 0.47 -
EDi041-A p38 0.19 -
EDi042-A p17 0.43 -
EDi043-A
EDi044-A p13 0.41 -
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